All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VHH72-FC,Ad26.COV2-S
Therapeutic Area: Infections and Infectious Diseases Product Name: VHH72-FC
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $27.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 28, 2020
Details:
Lead asset VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
Details:
The new vaccine is intended specifically for populations at high risk. It is also planned to guard against potential viral mutations by targeting conserved epitopes of the entire CoV-2 genome.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ZIP-1642
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2020
Details:
ZIPHIUS Therapeutics has prioritized its resources to intensify the development of ZIP-1642, a vaccine against the novel coronavirus.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
